Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

702

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Colorectal Cancer
Bladder Cancer
Gastric Cancer
Biliary Cancer
Cervical Cancer
Endometrial Cancer
Small Cell Lung Cancer Only in Module 5

Interventions

DRUG: AZD5305
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: T- Dxd
DRUG: Dato-DXd
DRUG: Camizestrant

Sponsor

AstraZeneca